⌕
Nuvation Bio · NUVB · NYSE
Tenet 37 · Weak
Compare
$3.90+1.56%At closeTenet 37 · Weak
$3.90+0.06 (+1.56%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Nuvation Bio (NUVB) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is NUVB's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 16, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting

With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was 81.5% in patients with Grade 2 IDH1-mutant glioma Patients achieved a median target lesion reductio…

NUVB +1.6% todayRead at source ↗
● Defense WorldNov 15, 2026 · 09:53 ET
ACT Capital Partners L.P. Buys 579,500 Shares of Nuvation Bio Inc. $NUVB

ACT Capital Partners L.P. bought a new position in Nuvation Bio Inc. (NYSE: NUVB) during the third quarter, according to the company in its most recent filing with the SEC. The firm bought 579,500 shares of the company's…

NUVB +1.6% todayRead at source ↗
● PRNewsWireNov 10, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, P…

NUVB +1.6% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 10:03 ET
Nuvation Bio: The Market Is Counting New Starts While IBTROZI Stacks Patients

Nuvation Bio's Ibtrozi's roughly 50-month first-line durability means revenue depends on patients staying on therapy, not just new starts. Q3 Ibtrozi revenue rose 18% sequentially to $27.5 million, even with new starts f…

NUVB +1.6% todayRead at source ↗
● MarketBeatNov 8, 2026 · 11:14 ET
What Nuvation Bio (NUVB) Said on Its Q3 Earnings Call

Nuvation Bio NYSE: NUVB reported $45 million in third-quarter 2026 revenue as U.S. sales of lung cancer treatment IBTROZI rose 18% from the previous quarter, even as the company said new patient starts declined across th…

NUVB +1.6% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 22:14 ET
Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) Q3 2026 Earnings Call Transcript…

NUVB +1.6% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 18:51 ET
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue Estimates

Nuvation Bio Inc. (NUVB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.16 per share a year ago.…

NUVB +1.6% todayRead at source ↗
● PRNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business Update

Achieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI ® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and established as the ROS1 ma…

NUVB +1.6% todayRead at source ↗
● PRNewsWireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting

Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies Poster featuring Phase 2 results to be pres…

NUVB +1.6% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries

New sites in the UK, France, Sweden, Germany, Italy and Spain will add to the global footprint of the pivotal SIGMA study NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company …

NUVB +1.6% todayRead at source ↗
● PRNewsWireOct 21, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026

NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a c…

NUVB +1.6% todayRead at source ↗
● Defense WorldSep 30, 2026 · 06:44 ET
Nuvation Bio Inc. (NYSE:NUVB) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Nuvation Bio Inc. (NYSE: NUVB - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve analysts that are currently covering the company, Marketbeat.com reports. One equities research…

NUVB +1.6% todayRead at source ↗
● PRNewsWireSep 17, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer

Updated label reflects TRUST-I TKI-naïve median duration of response of nearly 50 months No changes to the safety sections of labeling with longer follow-up and no new safety signals identified Approval comes four months…

NUVB +1.6% todayRead at source ↗
● Seeking AlphaSep 15, 2026 · 12:11 ET
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript…

NUVB +1.6% todayRead at source ↗
● PRNewsWireSep 15, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer

Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among pat…

NUVB +1.6% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 13:47 ET
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript…

NUVB +1.6% todayRead at source ↗
● BenzingaSep 4, 2026 · 07:07 ET
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Nuvation Bio Inc. (NYSE:NUVB) is a “pure spec.”…

NUVB +1.6% todayRead at source ↗
● Zacks Investment ResearchSep 3, 2026 · 10:55 ET
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in ear…

NUVB +1.6% todayRead at source ↗
● PRNewsWireSep 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Nuvation Bio to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.…

NUVB +1.6% todayRead at source ↗
● Zacks Investment ResearchAug 31, 2026 · 13:01 ET
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why

Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).…

NUVB +1.6% todayRead at source ↗
● PRNewsWireAug 20, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma

Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA stud…

NUVB +1.6% todayRead at source ↗
● Zacks Investment ResearchAug 18, 2026 · 10:56 ET
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know

The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising ea…

NUVB +1.6% todayRead at source ↗

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just NUVB · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.